Latest Triple-negative breast cancer Stories
Analysis of Phase I Trial indicates Safety and positive immune response data in 21 of 21 patients administered Folate Receptor Alpha Vaccine for breast and ovarian cancers SEATTLE,
SAN ANTONIO, December 11, 2014 /PRNewswire/ -- - The first study in the world combining Reparixin, an oral inhibitor of CXCR1/2, with standard
Studies Using Caris Molecular Intelligence(TM) Identify Standard as well as Novel Therapeutic Options Based on Molecular Characterization of Individual Patients' Tumors IRVING, Texas,
A University of Colorado Cancer Center study being presented at the San Antonio Breast Cancer Symposium shows that triple negative breast cancer cells process tryptophan to promote survival while
Over-expressed gene in triple negative breast cancer offers new diagnostics for risk assessment SINGAPORE, Dec 1, 2014
Results Published in Cancer Epidemiology, Biomarkers & Prevention Demonstrate Utility of Caris Molecular Intelligence(TM) in Exploring Expression of Targetable Immune Proteins IRVING,
The cancer drug eribulin, originally developed from sea sponges, could give women with advanced triple negative breast cancer an average of five extra months of life
WORCESTER, Mass. and TORONTO, Oct.
NORWALK, Conn., Oct.